Mesothelioma Candidate VT3989 Advances Toward Potential Registrational Phase 3 Study

According to a recent LinkedIn post from Vivace Therapeutics Inc, an episode of MesoTV sponsored by the Mesothelioma Applied Research Foundation features Dr. Timothy Yap of UT MD Anderson Cancer Center discussing the company’s VT3989-001 trial. The post describes VT3989 as a YAP/TEAD inhibitor aimed at disrupting intracellular signals that promote mesothelioma cell growth and survival.

The LinkedIn post highlights what it characterizes as compelling efficacy in both pleural and non-pleural refractory mesothelioma, alongside a favorable safety profile with few treatment-related adverse events above Grade 3. The post further suggests that these clinical results support advancement into a registrational third-line Phase 3 study in mesothelioma.

For investors, the prospect of a registrational Phase 3 trial in a refractory mesothelioma setting could indicate that VT3989 is progressing toward a potential approval pathway, contingent on future data and regulatory feedback. A successful late-stage outcome could position Vivace Therapeutics Inc within a niche but high-need oncology segment, potentially enhancing its strategic value to larger pharmaceutical partners or acquirers.

However, the LinkedIn post does not disclose detailed efficacy metrics, trial design parameters, or timelines, limiting visibility into the robustness and durability of the reported signals. Investors may view the mention of a favorable safety profile and a proposed Phase 3 direction as encouraging but still subject to significant clinical, regulatory, and financing risks inherent in oncology drug development.